Results 211 to 220 of about 73,620 (322)

Risk-stratified treatment of sonrotoclax with chemotherapy in newly diagnosed acute myeloid leukemia: a study protocol. [PDF]

open access: yesFuture Oncol
Zhang Y   +12 more
europepmc   +1 more source

The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AML

open access: yesBritish Journal of Haematology, EarlyView.
Summary IKZF1 mutations are recurrent alterations in acute myeloid leukaemia (AML), and hotspot point mutation, N159S, has recently been associated with unique gene expression and adverse risk. To better understand the molecular and clinical associations of IKZF1 N159S‐mutated AML, we performed a pooled analysis of 4136 AML patients.
Sebastian Stasik   +18 more
wiley   +1 more source

Are we ignoring sex differences in haematological malignancies? A call for improved reporting

open access: yesBritish Journal of Haematology, EarlyView.
A large body of data indicates that there are sex differences in the incidence of haematological malignancies, their clinical presentation and molecular profiles, and possibly also their aetiologies. Furthermore, sex‐related differences exist in treatment tolerability and outcomes.
Ora Paltiel   +2 more
wiley   +1 more source

Therapeutic drug monitoring of imatinib in paediatric chronic myeloid leukaemia: Data from a real‐world setting

open access: yesBritish Journal of Haematology, EarlyView.
Therapeutic drug monitoring (TDM) of imatinib is reported from a real‐world study in 66 children with paediatric Chronic Myeloid Leukemia (pCML). TDM allows dose adjustments, improving molecular response rates and is a step forward in personalized pCML care.
Meinolf Suttorp   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy